This report analyzes the Asia-pacific glaucoma treatment market by disease indication (closed angle glaucoma (CAG), open angle glaucoma (OAG), secondary glaucoma, congenital glaucoma and other), drug class (prostaglandin analogs (PGAS), alpha agonist, beta blockers, cholinergic drugs, carbonic anhydrase inhibitors, and others), surgery (laser iridotomy, laser trabeculoplasty, aqueous shunt surgery and peripheral iridectomy) and by end users (hospitals and home users); it also studies the top manufacturers in the market.
The Asia Pacific glaucoma treatment market was valued at USD 576.0 million in 2017 and is projected to reach USD 888.94 million in 2023, at a CAGR of 7.5% during the forecast period.
The major players in Asia-pacific glaucoma treatment market include:
• Novartis AG
• Pfizer Inc.
• Merck & Co.
• Ocular Therapeutix Inc
• pSivida Corp
• Icon Bioscience Inc
• Amorphex Therapeutics LLC.
The market revenue and share have been analyzed with respect to the following regions and countries:
Rest of Asia Pacific
On the basis of disease indication, the Asia-pacific glaucoma treatment market has been categorized into the following segments:
• Closed Angle Glaucoma (CAG)
• Open Angle Glaucoma (OAG)
• Secondary Glaucoma
• Congenital Glaucoma
On the basis of drug class, the Asia-pacific glaucoma treatment market has been categorized into the following segments:
• Prostaglandin Analogs (PGAs)
• Alpha Agonist
• Beta Blockers
• Cholinergic Drugs
• Carbonic Anhydrase Inhibitors
On the basis of surgery, the Asia-pacific glaucoma treatment market has been categorized into the following segments:
• Laser Iridotomy
• Laser Trabeculoplasty
• Aqueous Shunt Surgery
• Peripheral Iridectomy
On the basis of end users, the Asia-pacific glaucoma treatment market has been categorized into the following segments:
• Home Users
Analysis is conducted by industry experts who offer insight into industry structure, market segmentation, technology assessment, competitive landscape (CL), and market penetration, as well as on emerging trends. Besides primary interviews (~80%) and secondary research (~20%), their analysis is based on years of professional expertise in their respective industries. Our analysts also predict where the market will be headed in the next five to 10 years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories in different regions are estimated based on primary and secondary research.
Both the top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent sub-markets. The key players in the market were identified through secondary research, and their market contributions in the respective regions were determined through primary and secondary research. This entire process included the study of the annual and financial reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All the possible parameters that affect the market covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to arrive at the final quantitative and qualitative data.
Table of Content: Key Points
2 Research Methodology
3 Market Dynamics
4 Market Factor Analysis
5 Asia-Pacific Glaucoma Treatment Market, By Disease Indication
6 Asia-Pacific Glaucoma Treatment Market, By Drug Class
7 Asia-Pacific Glaucoma Treatment Market, By Surgery
Get in touch:
Company Name: Wiseguyreports.com
Contact Person: Norah Trent
Email: Send Email
Phone: +1 646 845 9349, +44 208 133 9349